Amanda L. Sharpe, Ph.D.

Assistant Professor

Department of Pharmaceutical Sciences

Phone (405) 271-6593 x47243

Fax (405) 271-7505

Email amanda-sharpe@ouhsc.edu


Summary

List of current grants


The Sharpe lab is interested in understanding the contribution of neuropeptides such as proopiomelanocortin, neurotensin, and corticotropin releasing factor to addiction, obesity, and age-related cognitive impairment, and in the development of therapeutics to treat these conditions. We use behavioral (operant conditioning), anatomical, pharmacological, and molecular approaches to address our research questions, often in combination with genetic mouse models. We are interested in the normal physiological role for these neuropeptides, as well as the adaptations that occur in this neurocircuitry under the conditions of obesity, food restriction, and chronic drug use. The long-term goals of our lab are to 1) elucidate the pharmacology and neurocircuitry involved in the regulation of appetite for and consumption of rewards (both food and drug), and 2) to determine the contribution of hypothalamic neuropeptides to age-related conditions such as obesity and cognitive decline.



Education & Experience

B.S. in Pharmacy

Ohio Northern University, Ada, OH

1997

Ph.D. in Pharmacology

Wake Forest University, Winston-Salem, NC

2002

Postdoc in Behavioral Neuroscience

Oregon Health & Science University, Portland, OR

2007


Grants

Effect of obesity on proopiomelanocortin regulation of reward and feeding

Presbyterian Health Foundation

07/01/2018 - 06/30/2019

Effects of dietary restriction on age-related neurophysiological adaptations: From behavior to single dopaminergic neurons

Oklahoma Medical Research Foundation

05/01/2018 - 04/30/2021


Publications & Presentations

1 2 3 4 > >>
  1. Lynch W B, Tschumi C W, Sharpe A, Branch S Y, Chen C, Ge G, Li S, Beckstead M J. Progressively disrupted somatodendritic morphology in dopamine neurons in a mouse Parkinson's model. Movement disorders : official journal of the Movement Disorder Society. 2018; 33 : 1928-1937
  2. Dominguez-Lopez S, Piccart E, Lynch W B, Wollet M B, Sharpe A, Beckstead M J. Antagonism of Neurotensin Receptors in the Ventral Tegmental Area Decreases Methamphetamine Self-Administration and Methamphetamine Seeking in Mice. The international journal of neuropsychopharmacology. 2018; 21 : 361-370
  3. Logan S, Owen D, Chen S, Chen W J, Ungvari Z, Farley J R, Csiszar A, Sharpe A, Loos M, Koopmans B, Richardson A, Sonntag W E. Simultaneous assessment of cognitive function, circadian rhythm, and spontaneous activity in aging mice. GeroScience. 2018; 40 : 123-137
  4. Dominguez-Lopez S, Piccart E, Lynch W B, Wollet M B, Sharpe A, Beckstead M J. Antagonism of neurotensin receptors in the ventral tegmental area decreases methamphetamine self-administration and methamphetamine seeking in mice. The international journal of neuropsychopharmacology. 2017
  5. Sharpe A, Varela E, Beckstead M J. Systemic PD149163, a neurotensin receptor 1 agonist, decreases methamphetamine self-administration in DBA/2J mice without causing excessive sedation. PloS one. 2017; 12 : e0180710
1 2 3 4 > >>